Viewing Study NCT06512220



Ignite Creation Date: 2024-10-26 @ 3:35 PM
Last Modification Date: 2024-10-26 @ 3:35 PM
Study NCT ID: NCT06512220
Status: NOT_YET_RECRUITING
Last Update Posted: None
First Post: 2024-07-16

Brief Title: Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression SYNVEST
Sponsor: None
Organization: None

Study Overview

Official Title: Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression SYNVEST
Status: NOT_YET_RECRUITING
Status Verified Date: 2024-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: SYNVEST
Brief Summary: Limit 5000 characters Psilocybin the chemical component of magic mushrooms has been administered with psychotherapy in several randomized clinical trials RCTs showing large and sustained antidepressant effects In healthy volunteers the psychedelic effects of psilocybin have been shown to be blocked by administration of certain medications such as risperidone

The purpose of this study is to use an established SV2A radiotracer produced at our Centre to determine the feasibility of integrating PET imaging in to psilocybin trials The preliminary imaging data will assess whether psilocybins antidepressant effects are related to changes in synaptic density in adults with TRD and whether any changes in synaptic density are associated with psilocybins actions on the 5-HT2AR
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None